Memphis Pharmaceuticals results, Q3 2023
Net profit, assets, equity and cash flow for Q3 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit7.5 millionEGP · −34.3% vs the same period a year earlier
Total assets656 millionEGP · +28.2% vs the same period a year earlier
Shareholders' equity57.94 millionEGP · +483.7% vs the same period a year earlier
Operating cash flow-56.73 millionEGP · −192.1% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q3 2023 was about 7.5 million EGP, down −34.3% from 11.41 million EGP in Q3 2022.
- Total assets at the end of Q3 2023 were about 656 million EGP, and shareholders' equity about 57.94 million EGP.
- Operating cash flow for Q3 2023 was negative at 56.73 million EGP.
Key lines against the same period a year earlier
This periodQ3 2022Change
Net profit7.5 million11.41 million−34.3%
Gross profit36.06 million35.64 million+1.2%
Total assets656 million512 million+28.2%
Total liabilities598 million527 million+13.5%
Shareholders' equity57.94 million-15.1 million+483.7%
Total liabilities and equity656 million512 million+28.2%
Operating cash flow-56.73 million61.58 million−192.1%
Investing cash flow-401 thousand-1.7 million+76.4%
Financing cash flow0——
Net change in cash-57.13 million59.88 million−195.4%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy